SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin (BNKR) is drawing significant attention for its expanding multi-chain utility and growing daily fee revenue, with the community actively speculating on an imminent price breakout to "drop a zero" as it sees aggressive buying. Despite this bullish sentiment and new exchange listings, a segment of the community cautions that it may be a pump and dump.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending after the abrupt departures of its CFO and General Counsel amid an accounting review citing material weaknesses and delayed financial filings, causing a sharp stock plunge as the community debates whether the steep sell-off is an overreaction or a severe governance concern.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is rallying sharply following a preliminary Q3 revenue pre-announcement that significantly exceeded both previous guidance and analyst consensus, igniting community excitement and reinforcing its role as a key "picks and shovels" beneficiary in the accelerating AI infrastructure build-out.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

AgomAb Therapeutics NV - ADR

AgomAb Therapeutics NV (AGMB), a recent IPO, is a major talking point due to its extreme volatility and rapid price movements, with community conversation heavily focused on a potential low float and the ongoing short squeeze narrative.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is experiencing a sharp sell-off following disappointing forward guidance for the current quarter, which is overshadowing a recent earnings beat. The market is actively debating the company's future, with many concerned about AI's impact on gig work while others see its own AI initiatives as a growth catalyst.

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Roivant Sciences Ltd

Roivant Sciences is drawing attention after reporting positive Phase 3 data for its dermatomyositis drug brepocitinib and divesting Dermavant, which has bolstered its significant cash reserves. The community is keenly discussing the substantial upside potential from ongoing LNP patent litigation involving major pharmaceutical companies, where Roivant holds a key interest through its Genevant stake.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display Technologies, Specialty Materials, Environmental Technologies, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computer, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Environmental Technologies segment focuses on manufacturing ceramic substrates and filter products for emissions control in mobile applications. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Corning (GLW) is trending after a significant agreement with Meta Platforms to supply fiber optics for AI data centers, firmly establishing its role as a critical infrastructure provider. The community is actively discussing its potential as a long-term wealth builder, driven by its diverse portfolio supporting the AI buildout and its continued ascent to new highs.

Fefe is a memecoin inspired by Matt Furie's book "Mindviscosity," published in 2020.  Follow FEFE, the alter ego of PEPE in the book “Mindviscosity” by Matt Furie.  Fefe is a main character in the book, who is a laid back and carefree frog living in a whimsical world. Fefe's relaxed and adventurous spirit captures the heart of this imaginative universe.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced - TAX: 0/0 This narrative has its roots in a fascinating story.  Join us and become part of the $FEFE community today!

Fefe

FEFE is currently drawing attention due to its community's strong promotion of its 'third frog' narrative, positioning it as a direct representation of Pepe's 4chan origins and a prime beta play to $PEPE. While detractors label it 'worthless garbage' and a 'scam,' its dedicated, community-owned movement consistently highlights its resilience in challenging market conditions and its potential for substantial growth.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Energy and Transportation, Financial Products, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Energy and Transportation segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The Financial Products segment provides financing alternatives to customers and dealers for Caterpillar products and services, as well as financing for power generation facilities. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925 and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillar is trending due to its pivotal role in providing power generation solutions for the expanding AI data center infrastructure, driving significant market interest and contributing to new highs, though some investors are debating its current valuation.

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Viatris Inc

Viatris is trending as investors debate its deep value and strategic pivot through new product launches like Inpefa internationally and active share buyback programs, while others remain cautious given past underperformance and persistent concerns over operational headwinds like the Indore facility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regencell Bioscience (NASDAQ:RGC) Shares Gap Up - Still a Buy?

Regencell Bioscience (NASDAQ:RGC) Shares Gap Up - What's Next...

Regencell Bioscience (NASDAQ:RGC) Trading Down 10.1% - Here's Why

Regencell Bioscience (NASDAQ:RGC) Shares Down 10.1% - Time to Sell...

Regencell Bioscience Holdings Limited (NASDAQ:RGC) Short Interest Down 28.1% in January

Regencell Bioscience Holdings Limited (NASDAQ:RGC - Get Free Report) was the recipient of a large decline in short interest during the month of January. As of January 15th, there was short interest...

Regencell Bioscience (NASDAQ:RGC) Stock Price Down 7.4% - Here's What Happened

Regencell Bioscience (NASDAQ:RGC) Shares Down 7.4% - What's Next...

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - What's Next?

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Here's Why...

Regencell Bioscience (NASDAQ:RGC) Trading Up 30% - Here's What Happened

Regencell Bioscience (NASDAQ:RGC) Shares Up 30% - Here's Why...

Regencell Bioscience (NASDAQ:RGC) Trading Down 7.8% - What's Next?

Regencell Bioscience (NASDAQ:RGC) Trading Down 7.8% - Here's What Happened...

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Should You Sell?

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Time to Sell...

Regencell Bioscience (NASDAQ:RGC) Shares Gap Up - Here's What Happened

Regencell Bioscience (NASDAQ:RGC) Shares Gap Up - Still a Buy...

<ul class="summary-bullets"><li>Regencell stated in an October SEC filing that it may be required to curtail or discontinue its operations in the future.</li><li>In the 2025 and 2024 fiscal years, Regencell reported a net loss of $3.58 million and $4.36 million, respectively.</li><li>The company had indicated that it anticipates incurring additional losses before realizing any revenues.</li></ul>Shares of Regencell Bioscience Holdings (RGC) have been drawing significant investor attention after gaining nearly 152% in the first four trading sessions of 2026.Following Wednesday’s relentless rally, the shares continued to climb in Thursday’s pre-market trade as well, rising by over 20% at the time of writing.While the bulk of the recent surge has come in 2026, RGC stock is still up nearly 218% since October 31, despite the company flagging a “substantial doubt” about its ability to continue as a going concern.<figure class="image"><img src="https://news.stocktwits-cdn.com/RGC_stock_chart_jpg_b4d92bf445.webp" alt="RGC stock performance from Jan. 1, 2025 to Jan. 7, 2025" width="1516" height="417"><figcaption>RGC stock performance from Jan. 1, 2025 to Jan. 7, 2025 | Koyfin</figcaption></figure><h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits regarding Regencell Bioscience was trending in the ‘bullish’ territory at the time of writing.One bullish user thinks that traders shorting the stock are in “huge trouble now.”<stembedurl>https://stocktwits.com/elbardinnyo/message/641188884</stembedurl>Another user said they treat it as a momentum-only stock.<stembedurl>https://stocktwits.com/Faniabh/message/641180065</stembedurl><h2 class="st-heading-2">RGC’s Going Concern Flag</h2>In a filing with the U.S. Securities and Exchange Commission in October 2025, the company said that there is a “substantial doubt” about its ability to continue as a going concern.It added that this indicates the company may be required to curtail or discontinue its operations in the future.“If we discontinue our operations, you may lose all of your investment,” Regencell said, adding that it anticipates incurring additional losses before realizing any revenues. In the 2025 and 2024 fiscal years, Regencell reported a net loss of $3.58 million and $4.36 million, respectively.Regencell is an early-stage company focusing on research, development, and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder.<a href="https://stocktwits.com/symbol/RGC">RGC stock</a> is up 152% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-hele-stock-falling-today/cmUb4SeR4Po">HELE Stock Slides Pre-market As Tariff Headwinds Trigger FY26 Earnings Guidance Cut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

RGC Stock Gains 20% Pre-Market — Retail Says Shorts Are In ‘Huge Trouble’

Regencell shares are up nearly 218% since October 31, despite the company flagging a “substantial doubt” about its ability to continue as a going concern.

Why Is RGC Stock Soaring Today?

Equity

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

RGC
Regencell Bioscience Holdings Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings:

Historical Earnings

Latest RGC News

RGCRegencell Bioscience Holdings Ltd